Contrasting CARGO Therapeutics (NASDAQ:CRGX) and OKYO Pharma (NASDAQ:OKYO)

CARGO Therapeutics (NASDAQ:CRGX) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Risk & Volatility

CARGO Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500.

Insider and Institutional Ownership

93.2% of CARGO Therapeutics shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 1.4% of CARGO Therapeutics shares are owned by company insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares CARGO Therapeutics and OKYO Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CARGO Therapeutics	N/A	N/A	-$98.15 million	($4.26)	-0.88
OKYO Pharma	N/A	N/A	-$16.83 million	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for CARGO Therapeutics and OKYO Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CARGO Therapeutics	1	6	0	0	1.86
OKYO Pharma	0	0	1	0	3.00

CARGO Therapeutics presently has a consensus price target of $15.00, suggesting a potential upside of 297.88%. OKYO Pharma has a consensus price target of $7.00, suggesting a potential upside of 527.80%. Given OKYO Pharma’s stronger consensus rating and higher possible upside, analysts plainly believe OKYO Pharma is more favorable than CARGO Therapeutics.

Profitability

This table compares CARGO Therapeutics and OKYO Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CARGO Therapeutics	N/A	-38.16%	-33.94%
OKYO Pharma	N/A	N/A	N/A

Summary

OKYO Pharma beats CARGO Therapeutics on 7 of the 9 factors compared between the two stocks.

About CARGO Therapeutics

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.